151 related articles for article (PubMed ID: 15686961)
1. L-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain.
Bezard E; Gross CE; Qin L; Gurevich VV; Benovic JL; Gurevich EV
Neurobiol Dis; 2005 Mar; 18(2):323-35. PubMed ID: 15686961
[TBL] [Abstract][Full Text] [Related]
2. Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment.
Ahmed MR; Bychkov E; Gurevich VV; Benovic JL; Gurevich EV
J Neurochem; 2008 Mar; 104(6):1622-36. PubMed ID: 17996024
[TBL] [Abstract][Full Text] [Related]
3. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
[TBL] [Abstract][Full Text] [Related]
4. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
5. Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation.
Ahmed MR; Gurevich VV; Dalby KN; Benovic JL; Gurevich EV
J Pharmacol Exp Ther; 2008 Apr; 325(1):276-83. PubMed ID: 18178904
[TBL] [Abstract][Full Text] [Related]
6. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets.
Lastres-Becker I; Cebeira M; de Ceballos ML; Zeng BY; Jenner P; Ramos JA; Fernández-Ruiz JJ
Eur J Neurosci; 2001 Dec; 14(11):1827-32. PubMed ID: 11860478
[TBL] [Abstract][Full Text] [Related]
7. Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity.
Hurlé MA
J Neurochem; 2001 Apr; 77(2):486-92. PubMed ID: 11299311
[TBL] [Abstract][Full Text] [Related]
8. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
9. G protein-coupled receptor kinases as regulators of dopamine receptor functions.
Gurevich EV; Gainetdinov RR; Gurevich VV
Pharmacol Res; 2016 Sep; 111():1-16. PubMed ID: 27178731
[TBL] [Abstract][Full Text] [Related]
10. Effect of Tianqi antitremor granules on behavioral manifestations and expression of G protein-coupled receptor kinase 6 and β-arrestin1 in levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Wu N; Yang X; Song L; Wei J; Liu Z
Drug Des Devel Ther; 2013; 7():1481-9. PubMed ID: 24376341
[TBL] [Abstract][Full Text] [Related]
11. G protein-coupled receptor kinases, beta-arrestin-2 and associated regulatory proteins in the human brain: postmortem changes, effect of age and subcellular distribution.
Grange-Midroit M; García-Sevilla JA; Ferrer-Alcón M; La Harpe R; Walzer C; Guimón J
Brain Res Mol Brain Res; 2002 May; 101(1-2):39-51. PubMed ID: 12007830
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats.
Ahmed MR; Bychkov E; Kook S; Zurkovsky L; Dalby KN; Gurevich EV
Exp Neurol; 2015 Apr; 266():42-54. PubMed ID: 25687550
[TBL] [Abstract][Full Text] [Related]
13. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
14. Different G protein-coupled receptor kinases govern G protein and beta-arrestin-mediated signaling of V2 vasopressin receptor.
Ren XR; Reiter E; Ahn S; Kim J; Chen W; Lefkowitz RJ
Proc Natl Acad Sci U S A; 2005 Feb; 102(5):1448-53. PubMed ID: 15671180
[TBL] [Abstract][Full Text] [Related]
15. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
[TBL] [Abstract][Full Text] [Related]
16. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
Guigoni C; Doudnikoff E; Li Q; Bloch B; Bezard E
Neurobiol Dis; 2007 May; 26(2):452-63. PubMed ID: 17350277
[TBL] [Abstract][Full Text] [Related]
17. Basal ganglia serotonin 1B receptors in parkinsonian monkeys with L-DOPA-induced dyskinesia.
Riahi G; Morissette M; Samadi P; Parent M; Di Paolo T
Biochem Pharmacol; 2013 Oct; 86(7):970-8. PubMed ID: 23954709
[TBL] [Abstract][Full Text] [Related]
18. NMDA receptor regulation of levodopa-induced behavior and changes in striatal G protein-coupled receptor kinase 6 and β-arrestin-1 expression in parkinsonian rats.
Wu N; Song L; Yang X; Yuan W; Liu Z
Clin Interv Aging; 2013; 8():347-52. PubMed ID: 23569367
[TBL] [Abstract][Full Text] [Related]
19. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Riahi G; Morissette M; Parent M; Di Paolo T
Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
[TBL] [Abstract][Full Text] [Related]
20. Effect of chronic l-DOPA treatment on 5-HT(1A) receptors in parkinsonian monkey brain.
Riahi G; Morissette M; Lévesque D; Rouillard C; Samadi P; Parent M; Di Paolo T
Neurochem Int; 2012 Dec; 61(7):1160-71. PubMed ID: 22940695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
